Browsing Tag

ART26.12

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon…

Eli Pacheco Jul 19, 2023 0

SOLANA BEACH, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to…

Health

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive…

Eli Pacheco Jun 27, 2023 0

ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy ART26.12 targeting global…

Health

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5…

Eli Pacheco Jun 28, 2022 0

SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to…